EFUDEX (fluorouracil) by Pfizer is nucleic acid synthesis inhibitors [moa]. First approved in 1970.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
EFUDEX (fluorouracil) is a topical cream nucleoside metabolic inhibitor that works by inhibiting nucleic acid synthesis to treat actinic keratosis and other skin conditions. It is applied directly to affected skin areas and has been in use since 1970. This small-molecule chemotherapy agent is approaching loss of exclusivity with moderate competitive pressure in its indication space.
As a mature product approaching LOE with modest Part D spending, the brand team is likely focused on market defense and cost optimization rather than expansion.
Nucleic Acid Synthesis Inhibitors
Nucleoside Metabolic Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo
Worked on EFUDEX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on EFUDEX positions you in a mature-to-declining franchise where career impact is measured by defensive market share, cost efficiency, and transition planning rather than innovation or growth. This assignment suits professionals strong in portfolio optimization and GenRx strategy but offers limited upside for career progression seekers.